CN100358550C - Chinese traditional medicine for treating bradycardia - Google Patents
Chinese traditional medicine for treating bradycardia Download PDFInfo
- Publication number
- CN100358550C CN100358550C CNB2004100139415A CN200410013941A CN100358550C CN 100358550 C CN100358550 C CN 100358550C CN B2004100139415 A CNB2004100139415 A CN B2004100139415A CN 200410013941 A CN200410013941 A CN 200410013941A CN 100358550 C CN100358550 C CN 100358550C
- Authority
- CN
- China
- Prior art keywords
- bradycardic
- dosage
- aconiti lateralis
- oral preparation
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 230000036471 bradycardia Effects 0.000 title abstract description 7
- 208000006218 bradycardia Diseases 0.000 title abstract description 7
- 238000012545 processing Methods 0.000 claims abstract description 8
- 230000000059 bradycardiac effect Effects 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 7
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 abstract description 8
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 abstract description 7
- 229960005260 amiodarone Drugs 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 229960003712 propranolol Drugs 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000000661 pacemaking effect Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 4
- 241000545442 Radix Species 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 229960003404 mexiletine Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- -1 electuary Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a traditional Chinese medicament for treating bradycardia, which is an oral preparation obtained by processing 40 to 60% of astragalus and aconite as raw material. Pharmacodynamic tests on two slow cardiac rhythm models of amiodarone and propranolol of rats prove that the oral preparation can obviously increase bradycardic heart rates of the two models, and the long-term oral administration of the oral preparation is safe without toxic or side effect.
Description
One, technical field
The present invention relates to the bradycardic pharmaceutical composition of a kind of treatment, exactly is to be the bradycardic Chinese medicine of treatment of feedstock production with the vegetable Chinese herbal medicine.
Two, background technology
Bradycardia is the systemic disease based on heart change that a kind of multi-pathogenesis causes, and is in the majority with the old people.When heart rate slowed to a certain degree, minimizing in various degree appearred in each important organ blood supply, and clinical manifestation dizziness, symptom such as uncomfortable in chest, weak often need surgical operation that artificial cardiac pacemaker is installed.If the drug main atropic category of clinical raising heart rate is rapid-action, effect is obvious, but it is of short duration to hold time, and has xerostomia, fever sensation of the face, elderly men untoward reaction such as dysuria often to occur.Clinical antiarrhythmic Agents commonly used also has cardiac tonic such as amiodarone, digoxin, but heart rate is obviously slowed down.The bradycardia that causes of amiodarone particularly still finds no the medicine (atropine is invalid) of effect so far in the world.Therefore, must stop using.Abroad,, use heavy dose of amiodarone arrhythmia, when serious bradycardia occurring, often must implant a pacemaker especially in the U.S..
Three, summary of the invention
Technical scheme of the present invention is the oral formulations by two flavor Chinese crude drug processing of following percentage by weight:
The Radix Astragali 40～60%
Radix Aconiti Lateralis Preparata 40～60%.
Preferred percentage by weight is:
The Radix Astragali 50%
Radix Aconiti Lateralis Preparata 50%.
Described oral formulations is any dosage form that allows on the pharmaceutics, as decoction, granule, tablet, electuary, capsule etc.
Be soaked in water 1～2 hour after Huang Shi, Radix Aconiti Lateralis Preparata be mixed in proportion, add 8～10 times of water gaging reflux, extract, twice then, separate, merge aqueous extract twice, dehydration concentrates and is extractum, at this moment can add adjuvant mix homogeneously post-treatment and obtain corresponding dosage forms; Perhaps will process corresponding dosage forms with the adjuvant mix homogeneously again behind the extract dry.
Evidence is carried out precipitate with ethanol with above-mentioned water extract with 30～50% ethanol and is handled back reprocessing corresponding preparation, and its effect is equally matched.
The Radix Astragali is traditional traditional tonic medicine, merit tool tonifying Qi and lifting yang, and benefit is defended consolidating superficial resistance, inducing diuresis to remove edema, holder skin ulcer granulation promoting.The Shennong's Herbal row be " top grade ".
Radix Aconiti Lateralis Preparata can on help heart-yang, middle warming the spleen sun, following kidney-replenishing is " the recuperating depleted YANG and rescuing the patient from collapse first product medicine ".Bradycardia belongs to traditional Chinese medical science retarded pulse disease category.The Chinese medical discrimination typing is: deficiency of heart-QI disease, spleen deficiency syndrome, the heart-yin are lost deficient syndrome, heart-yang stasis-eliminating disease, the turbid numbness resistance of expectorant disease.This preparation is applicable to deficiency of heart-QI disease, heart-yang stasis-eliminating disease type.
The present invention has carried out pharmacodynamics and toxicologic study respectively with the capsule of processing, and for trial product pace-making capsule by name, the result is as follows.
1, pharmacodynamics test: adopt two kinds of mexiletine models of rat amiodarone and propranolol respectively, three kinds of dosage of ig pace-making capsule extractum 0.62,0.31,0.155g extractum/kg (amounting to crude drug 4,2,1g/kg) treat 2 week and 3 weeks of propranolol mexiletine of rat amiodarone mexiletine respectively.The result shows, pace-making capsule height, in can obviously the raise heart rate of amiodarone bradycardia rat of two kinds of dosage, and its blood pressure do not had obvious influence.Also can obviously the raise heart rate of propranolol mexiletine rat model of high dose.
2, acute toxicity test: carried out the acute toxicity test of two kinds of approach of pace-making capsule 's content (dry extract).Result of the test shows: mice ig administration, LD
50=21.31g.kg
-1(amount to crude drug 136.60g.kg
-1, be equivalent to 88.79 times of clinical application amounts), 95% fiducial limit 17.96-25.29g.kg
-1(amount to crude drug 115.12-162.11g.kg
-1).The ip in mice administration, LD
50=2.91g.kg
-1(amount to crude drug 18.65g.kg
-1), 95% fiducial limit 2.51-3.39g.kg
-1(amount to crude drug 16.09-21.73g.kg
-1).
3, long term toxicity test: pace-making capsule 0.33,1,3.1g extractum/kg (amount to crude drug 2.5,7.5,22.5g.kg
-1) ig90 days continuously, the result shows, compares with the normal control group, and three dosage group GLU are starkly lower than matched group, and high, middle dosage group T-BIL is apparently higher than matched group; High dose group thyroid, weight coefficient of testis are apparently higher than matched group; In 2 weeks after the drug withdrawal, more than change all and recover.Compare with matched group, other blood biochemical is learned index and the equal no significant difference of organ coefficient.Compare with the normal control group, three kinds of dosage of pace-making capsule are observed the general situation of rat, routine urinalysis, hematology and histopathology does not all have obviously influence.
Three kinds of dosage of pace-making capsule 0.17,0.5,1g.kg
-1Extractum (is amounted to crude drug 1,3 and 6g.kg
-1.d
-1) ig90 days continuously, the result shows, and No. 8 dogs of high dose group (♀) occurred outside the sialorrhea after the each administration of the 9th week in about 5-10 minute, and the behavioral activity of three dosage groups and all the other each dogs of normal control group is normal.Compare with matched group, ig90 days weight gain value of three dosage groups of pace-making capsule (0-13 week) is all not as matched group, and high, middle dosage group has notable difference, and low dose group weight gain value and matched group be there was no significant difference relatively.Three dosage ig90 of pace-making capsule days, dog hematology, blood biochemical index, routine urinalysis and electrocardiogram all there is not obvious influence.Pace-making capsule low dose group medication 3 months are described, are non-toxic reaction dosage.
Four, the specific embodiment
Be example with the capsule now, non-limiting examples is described below.
1, get 40 parts of the Radixs Astragali, 60 parts of Radix Aconiti Lateralis Preparatas add 10 times of water gagings and soaked 1～2 hour after the mixing, and reflux is 2～3 hours then, separates to obtain aqueous extract.Filtering residue adds 8 times of water gagings again and refluxed 2 hours, separates.Merge aqueous extract twice, dehydration concentrates and obtains extractum, and drying obtains extract powder again.Per 100 portions of mixing raw medicinal herbs can obtain the extract powder about 21 parts.If aqueous extract can obtain 15～18 parts of extract powders after the precipitate with ethanol remove impurity.
With extract powder and adjuvant micropowder silica gel--the dextrin mix homogeneously adorns 0
#Capsule, every about 0.4～0.45g of loading amount, wherein effective ingredient amounts to raw medicinal herbs 1.3～1.4g, day clothes three times, each three.
2, get 45 parts of the Radixs Astragali, 55 parts of Radix Aconiti Lateralis Preparatas, processing is with embodiment 1.
3, get each 50 parts of the Radix Astragali, Radix Aconiti Lateralis Preparatas, processing is with embodiment 1.
4, get 55 parts of the Radixs Astragali, 45 parts of Radix Aconiti Lateralis Preparatas, processing is with embodiment 1.
5, get 60 parts of the Radixs Astragali, 40 parts of Radix Aconiti Lateralis Preparatas, processing is with embodiment 1.
Claims (3)
1, the bradycardic Chinese medicine of a kind of treatment is characterized in that: by the oral formulations of the Chinese crude drug of following percentage by weight processing:
The Radix Astragali 40～60%
Radix Aconiti Lateralis Preparata 40～60%
2, the bradycardic Chinese medicine of treatment according to claim 1 is characterized in that: the percentage by weight of two flavor Chinese crude drugs is:
The Radix Astragali 50%
Radix Aconiti Lateralis Preparata 50%
3, the bradycardic Chinese medicine of treatment according to claim 1 and 2, it is characterized in that: described oral formulations is a capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100139415A CN100358550C (en) | 2004-01-15 | 2004-01-15 | Chinese traditional medicine for treating bradycardia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100139415A CN100358550C (en) | 2004-01-15 | 2004-01-15 | Chinese traditional medicine for treating bradycardia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1557393A CN1557393A (en) | 2004-12-29 |
| CN100358550C true CN100358550C (en) | 2008-01-02 |
Family
ID=34351196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100139415A Expired - Fee Related CN100358550C (en) | 2004-01-15 | 2004-01-15 | Chinese traditional medicine for treating bradycardia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100358550C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107551217B (en) * | 2017-08-23 | 2020-07-03 | 上海中医药大学附属曙光医院 | Formula of traditional Chinese medicine composition for treating chronic heart failure by promoting expression of sarcoplasmic reticulum calcium pump |
-
2004
- 2004-01-15 CN CNB2004100139415A patent/CN100358550C/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 心缓康胶囊的制备与临床应用. 刘金凤等.中国医院药学杂志2003，第23卷第9期. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1557393A (en) | 2004-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106729274A (en) | Kidney supplementing yang invigorating health care health composition, Preparation Method And The Use | |
| CN101450166A (en) | Traditional Chinese medicine composition with blood-sugar function and preparation method thereof | |
| CN101450095A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN100502833C (en) | New preparation method of Tibetan medicine Qingpeng ointment | |
| CN101284050B (en) | Corydalis tuber water soluble part medicament and its preparation method and application | |
| CN100358550C (en) | Chinese traditional medicine for treating bradycardia | |
| CN103705774A (en) | Compound composition with effect of treating depression as well as preparation method and application thereof | |
| CN103223080B (en) | Traditional Chinese medicinal composition for tranquilizing mind by nourishing the heart and preparation method thereof | |
| CN103007159B (en) | Chinese medicinal preparation for correcting pancreas islet function | |
| CN102018852A (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN101444583A (en) | Medicament for curing neurasthenia | |
| CN105125885B (en) | It is a kind of to be used to prevent Chinese medicine composition of diabetes and preparation method thereof | |
| CN102091285A (en) | Medicinal preparation for clearing heat and restoring consciousness, preparation method thereof and application thereof | |
| CN101632730B (en) | Application of Chinese medicinal composition in preparing medicament for treating affective disorder | |
| CN100581566C (en) | Chinese medicine preparation for treating arrhythmia | |
| CN1246016C (en) | Compound formulation of traditional Chinese medicine for climacteric syndrome and preparation method | |
| CN101036714B (en) | Medicinal composition for treating and/or preventing diabetes | |
| CN104000871A (en) | Drug for treating myocardial ischemia | |
| CN102716448A (en) | Chinese patent medicine and TCM decoction capable of effectively curing nausea and vomiting | |
| CN100381132C (en) | Hypoglycemic Chinese medicine prepn and its production process | |
| CN1238013C (en) | Myocarditis treating Chinese medicine prepn | |
| CN102908508B (en) | Medicinal composition for treating seborrheic alopecia and preparation method thereof | |
| CN102302642A (en) | Medicament for treating chloasma and preparation method thereof | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| CN101450096A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080102 Termination date: 20140115 |